Nucl Med Mol Imaging.  2015 Sep;49(3):237-240. 10.1007/s13139-015-0321-9.

FDG-PET/CT in a Patient with Poor-Risk Non-Seminoma Testis with Mature Teratoma and Secondary Gliosarcoma: Multimodality Imaging for Guiding Multimodality Treatment

Affiliations
  • 1Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. e.quak@baclesse.unicancer.fr
  • 2Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
  • 3Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

Abstract

The value of F-18-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in detecting viable tumours in patients with metastasised nonseminomatous testicular cancer and residual and new masses post chemotherapy remains to be determined. We describe the case of a 41-year-old patient with metastasised nonseminomatous testicular cancer, with both retroperitoneal and extra-retroperitoneal residual masses post chemotherapy, for whom FDG-PET/CT guided major treatment decisions. FDG-PET/CT correctly identified the locations of viable tumour, as was proved by histology, and successfully guided surgery. In conclusion, in selected cases surveillance of patients with nonseminomatous testicular cancer with FDG-PET/CT can guide major treatment decisions when considering surgery for metastatic disease.

Keyword

FDG-PET/CT; Testicular cancer; Teratoma; Germ cell tumour

MeSH Terms

Adult
Drug Therapy
Electrons
Gliosarcoma*
Humans
Neoplasm Metastasis
Teratoma*
Testicular Neoplasms
Testis*
Full Text Links
  • NMMI
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr